First patient dosed in Phase 2 trial testing mirivadelgat for PH-ILD
The first participant has been dosed in a Phase 2 trial testing the experimental oral therapy mirivadelgat in people with pulmonary hypertension associated with interstitial lung disease (PH-ILD). The Phase 2 trial, called WINDWARD (NCT06475781), aims to enroll about 126 adults with PH-ILD, ages 18 to 85. Participants will…